PCUR-101
/ Pellficure
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
April 10, 2024
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
(clinicaltrials.gov)
- P1 | N=7 | Terminated | Sponsor: Pellficure Pharmaceuticals, Inc | N=48 ➔ 7 | Recruiting ➔ Terminated; Business Decision due to insufficient enrollment
Combination therapy • Enrollment change • Metastases • Trial termination • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
May 19, 2019
A phase I dose escalation study of PCUR-101 in men with metastatic castration-resistant prostate cancer (mCRPC).
(ASCO 2019)
- P1; "At the doses evaluated, PCUR-101 combined with ADT was seen to be safe and may prolong disease stability in men with mCRPC. A second phase I study is planned using a new drug formulation and PK assay. Clinical trial information: NCT03137758"
P1 data
September 29, 2022
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Pellficure Pharmaceuticals, Inc | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023
Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
March 04, 2021
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
(clinicaltrials.gov)
- P1; N=48; Recruiting; Sponsor: Pellficure Pharmaceuticals, Inc; Not yet recruiting ➔ Recruiting; Initiation date: Jan 2021 ➔ Apr 2021
Clinical • Combination therapy • Enrollment open • Trial initiation date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
December 21, 2020
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
(clinicaltrials.gov)
- P1; N=48; Not yet recruiting; Sponsor: Pellficure Pharmaceuticals, Inc
Clinical • Combination therapy • New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
March 09, 2020
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
(clinicaltrials.gov)
- P1; N=12; Terminated; Sponsor: Pellficure Pharmaceuticals, Inc; Active, not recruiting ➔ Terminated; Reformulation of study drug to help reduce the pill burden as higher doses are evaluated.
Clinical • Combination therapy • Trial termination
August 28, 2019
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
(clinicaltrials.gov)
- P1; N=12; Active, not recruiting; Sponsor: Pellficure Pharmaceuticals, Inc; Recruiting ➔ Active, not recruiting; N=48 ➔ 12
Clinical • Combination therapy • Enrollment change • Enrollment closed
1 to 7
Of
7
Go to page
1